Is Vertex Stock Outperforming the Dow?

With a market cap of $122.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology company focused on discovering, developing, and commercializing transformative medicines for serious diseases, particularly in areas of high unmet medical need. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex is best known for building the first and dominant class of therapies that treat the underlying cause of cystic fibrosis (CF), establishing a durable global franchise with blockbuster drugs such as Trikafta/Kaftrio.

Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Vertex fits this criterion perfectly, exceeding the mark.